The mutation at TP53 might confer a better response capacity to apoptosis and to stop cell cycle progression, all of which makes us rethink the necessity of deciphering the molecular status of TP53 prior to treating patients of neuroblastoma in order to standardize therapies with the aim of improving survival. The gene discussed is TP53; the disease is neuroblastoma.